AstraZeneca Aims to Redefine Breast Cancer Care with New Data Across the Treatment Spectrum at SABCS 2022
November 23, 2022
November 23, 2022
WILMINGTON, Delaware, Nov. 23 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
Data will show clinical opportunity in HR-positive advanced breast cancer for potential first-in-class AKT inhibitor capivasertib and next-generation oral SERD camizestrant
ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) data will reinforce potential to set new standards in HER2-targetable disease
Data for antibody drug conj . . .
* * *
Data will show clinical opportunity in HR-positive advanced breast cancer for potential first-in-class AKT inhibitor capivasertib and next-generation oral SERD camizestrant
ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) data will reinforce potential to set new standards in HER2-targetable disease
Data for antibody drug conj . . .